Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Recruiting

• Conditions: COVID-19 Pneumonia
• Interventions: Other: The group of patients who did not receive Lianhua Qingwen orally; Drug: The group of patients who received Lianhua Qingwen orally

• Registration Number: NCT05778318
• Lead Sponsor: Qianfoshan Hospital

Brief Summary

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-20
• Study First Submitted: 2023-03-20
• Study First Submitted QC: 2023-03-20
• Study First Posted: 2023-03-21
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-09
• Last Update Posted: 2023-05-11
• Primary Completion: 2024-04-30
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission.
• The clinical symptoms were classified as mild or ordinary.
• They have been vaccinated against the COVID-19.

Exclusion Criteria

• Patients receiving antiviral or antibiotic drugs
• Severe and critical patients with COVID-19.
• Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.
• Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.
• Allergic reaction to Lianhua Qingwen granules.
• Excluded patients treated with the same drug as Lianhua Qingwen.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control group	The group of patients who did not receive Lianhua Qingwen orally	Patients without Lianhua Qingwen treatment.
Observation Group	The group of patients who received Lianhua Qingwen orally	Patients with Lianhua Qingwen treatment.

Primary Outcome Measures

Name	Time	Method
Disappearance rate of symptoms	two weeks	Disappearance rate of symptoms (fever, fatigue, cough)

Trial Locations

Locations (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China; 🇨🇳 Jinan, Shandong, China